Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
GOG Foundation
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
AstraZeneca
The University of Hong Kong
Shandong University